Denosumab No Better than Bisphosphonates for Preventing Fracture, and the Cost Is Much ...
Sep 15, 2020 - This meta-analysis found no evidence that the monoclonal antibody denosumab reduces the risk of fracture more than bisphosphonates.
American Family Physician : POEMs
https://www.aafp.org/afp/2020/0915/p375a.html
Denosumab for Reducing Risk of Fractures in Postmenopausal Women - Medicine by the ...
May 1, 2019 - Denosumab appears to be effective in reducing the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. Treatment with denosumab does not increase the risk of cancer or death but might increase the risk of infection. However, more studies are required.
American Family Physician : Medicine by the Numbers
https://www.aafp.org/afp/2019/0501/od1.html
Duration of Bisphosphonate Therapy - FPIN's Help Desk Answers - American Family Physician
Apr 1, 2018 - Oral bisphosphonates significantly reduce clinical fracture risk at four years in women with postmenopausal osteoporosis (T-score less than −2.5). Treatment beyond five years is associated with further reductions in fractures in women with persistent femoral neck T-scores less than −2.5.
American Family Physician : FPIN's Help Desk Answers
https://www.aafp.org/afp/2018/0401/od1.html
Treating Low Vitamin D Levels Is Ineffective in Postmenopausal Women - POEMs - American...
Feb 15, 2016 - You do not have to treat a low vitamin D level if your patient is a typical community-dwelling postmenopausal woman younger than 75 years. The usual dosage of vitamin D, 800 IU (20 mcg) daily, will not increase levels even after a year of therapy and has little effect on calcium ...
American Family Physician : POEMs
https://www.aafp.org/afp/2016/0215/p315.html
Risks of Bisphosphonate Use - FPIN's Clinical Inquiries - American Family Physician
Nov 15, 2013 - Bisphosphonates are associated with a small risk of atypical femoral shaft fractures, which increases with duration of use. Bisphosphonates are associated with a small risk of osteonecrosis of the jaw, which is more common in patients who are older, female, or have poor dental hygiene ...
American Family Physician : FPIN's Clinical Inquiries
https://www.aafp.org/afp/2013/1115/p697.html
Zoledronic Acid (Reclast) for Osteoporosis - STEPS - American Family Physician
Aug 15, 2008 - Zoledronic acid, in combination with calcium and vitamin D, will reduce the risk of vertebral fractures, and to a lesser extent, hip fractures in women with osteoporosis. It decreases subsequent fractures and mortality in high-risk patients who have had a hip fracture. Zoledronic acid ...
American Family Physician : STEPS
https://www.aafp.org/afp/2008/0815/p508.html
Pharmacologic Prevention of Osteoporotic Fractures - American Family Physician
Oct 1, 2004 - Osteoporosis is characterized by low bone mineral density and a deterioration in the microarchitecture of bone that increases its susceptibility to fracture. The World Health Organization defines osteoporosis as a bone mineral density that is 2.5 standard deviations or more below the ...
American Family Physician : Article
https://www.aafp.org/afp/2004/1001/p1293.html
Postmenopausal Osteoporosis and Estrogen - Editorials - American Family Physician
Aug 15, 2003 - ...head-to-head comparisons of medical and nonmedical interventions would improve our current approach to osteoporosis prevention. A limited number of studies of nonmedical interventions, such as exercise, adequate intake of calcium and vitamin D,11 and the use of hip protectors in...
American Family Physician : Editorials
https://www.aafp.org/afp/2003/0815/p606.html
Bisphosphonates: Safety and Efficacy in the Treatment and Prevention of Osteoporosis - ...
May 1, 2000 - Osteoporosis affects more than 28 million Americans. With the advent of accessible and affordable diagnostic studies, awareness and recognition of this disease by patients and clinicians are growing. Osteoporotic fractures of the spine and hip are costly and associated with significant ...
American Family Physician : Article
https://www.aafp.org/afp/2000/0501/p2731.html
Raloxifene: A Selective Estrogen Receptor Modulator - American Family Physician
Sep 15, 1999 - Raloxifene is a selective estrogen receptor modulator that produces both estrogen-agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue. Because of its tissue selectivity, raloxifene may have fewer side effects than are...
American Family Physician : Article
https://www.aafp.org/afp/1999/0915/p1131.html
Prevention of Osteoporosis and Fractures - American Family Physician
Jul 1, 1999 - Osteoporosis and low bone density are associated with a risk of fracture as a result of even minimally traumatic events. The estimated lifetime risk of osteoporotic fracture is as high as 50 percent, especially in white and Asian women. The use of caffeine, tobacco and steroids is ...
American Family Physician : Article
https://www.aafp.org/afp/1999/0701/p194.html
navigate_before 1 navigate_next